A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK121-NX in Patients With Advanced Solid Tumors (NCT05627063)

🧪 Interventions in This Study

• ABSK121-NX (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (24 Sites)

• UC San Diego Moores Cancer Center — La Jolla, California
• Karmanos Cancer Institute — Detroit, Michigan
• Comprehensive Cancer Centers of Nevada — Las Vegas, Nevada
• Gabrail Cancer Center Research — Canton, Ohio
• Chongqing University Cancer Hospital — Chongqing, Chongqing Municipality
• The First Affiliated Hospital of Henan University of Science & Technology — Luoyang, Henan
• The First Affiliated Hospital of Zhengzhou University — Zhengzhou, Henan
• Hubei Cancer Hospital — Wuhan, Hubei
• Hunan Central Hospital — Changsha, Hunan
• The Affiliated Hospital of Inner Mongolia Medical University — Hohhot, Inner Mongolia
• The First Affiliated Hospital of Nanchang University — Nanchang, Jiangxi
• Jilin Cancer Hospital — Changchun, Jilin
• The First Hospital of China Medical University — Shenyang, Liaoning
• Shanghai East Hospital Tongji University — Shanghai, Shanghai Municipality
• Shanxi Provincial Cancer Hospital — Taiyuan, Shanxi
• West China School of Medicine/West China Hospital of Sichuan University — Chengdu, Sichuan
• Mianyang Central Hospital — Mianyang, Sichuan
• Zhejiang University Cancer Hospital — Hangzhou, Zhejiang
• Fujian Cancer Hospital (Department of Hepatobiliary and Pancreatic Oncology /Phase I Ward) — Fuzhou,
• Harbin Medical University Cancer Hospital (Gastroenterology Department 2nd Ward) — Haerbin,
• Zhongshan Hospital of Fudan University (Hepatological Surgery Department) — Shanghai,
• Zhongshan Hospital of Fudan University (Medical Oncology Department) — Shanghai,
• Liaoning Cancer Hospital (Phase I Ward) — Shenyang,
• Yantai Yuhuangding Hospital (Department of Medical Oncology, 1) — Yantai,

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Solid Tumor

• A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors — Houston, Texas
• A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor Cancer — Middletown, New Jersey
• A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer — Basking Ridge, New Jersey
• Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors — Chicago, Illinois
• A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors — New York, New York
• Concurrent Azeliragon With Craniospinal Irradiation — New York, New York

Explore by condition: All Solid Tumor clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.